Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome

Small molecule receptor tyrosine kinase inhibitors (SM-TKIs) are among a group of targeted cancer therapies, intended to be more specific to cancer cells compared with treatments, such as chemotherapy, hence reducing adverse events. Unfortunately, many patients report high levels of diarrhea, the pa...

Full description

Saved in:
Bibliographic Details
Published in:Integrative Cancer Therapies 2020, Vol.19, p.1534735420928493-1534735420928493
Main Authors: Secombe, Kate R., Van Sebille, Ysabella Z. A., Mayo, Bronwen J., Coller, Janet K., Gibson, Rachel J., Bowen, Joanne M.
Format: Article
Language:English
Subjects:
Cancer and the Microbiome
Chemotherapy
Diarrhea
Intestinal microflora
Investigations
Microbiomes
Pathogenesis
Protein-tyrosine kinase receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small molecule receptor tyrosine kinase inhibitors (SM-TKIs) are among a group of targeted cancer therapies, intended to be more specific to cancer cells compared with treatments, such as chemotherapy, hence reducing adverse events. Unfortunately, many patients report high levels of diarrhea, the pathogenesis of which remains under investigation. In this article, we compare the current state of knowledge of the pathogenesis of chemotherapy-induced diarrhea (CID) in comparison to SM-TKI–induced diarrhea, and investigate how a similar research approach in both areas may be beneficial. To this end, we review evidence that both treatment modalities may interact with the gut microbiome, and as such the microbiome should be investigated for its ability to reduce the risk of diarrhea.
ISSN:1534-7354
1552-695X
DOI:10.1177/1534735420928493